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Genome editing on human pluripotent stem cells (hPSCs) together with the development of protocols for
organ decellularization opens the door to the generation of autologous bioartiﬁcial hearts. Here we
sought to generate for the ﬁrst time a ﬂuorescent reporter human embryonic stem cell (hESC) line by
means of Transcription activator-like effector nucleases (TALENs) to efﬁciently produce cardiomyocyte-
like cells (CLCs) from hPSCs and repopulate decellularized human heart ventricles for heart engineer-
ing. In our hands, targeting myosin heavy chain locus (MYH6) with mCherry ﬂuorescent reporter by
TALEN technology in hESCs did not alter major pluripotent-related features, and allowed for the deﬁ-
nition of a robust protocol for CLCs production also from human induced pluripotent stem cells (hiPSCs)
in 14 days. hPSCs-derived CLCs (hPSCs-CLCs) were next used to recellularize acellular cardiac scaffolds.
Electrophysiological responses encountered when hPSCs-CLCs were cultured on ventricular decellular-
ized extracellular matrix (vdECM) correlated with signiﬁcant increases in the levels of expression of
different ion channels determinant for calcium homeostasis and heart contractile function. Overall, the
approach described here allows for the rapid generation of human cardiac grafts from hPSCs, in a total of
24 days, providing a suitable platform for cardiac engineering and disease modeling in the human
setting.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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The derivation of human embryonic stem cells (hESCs) [1]
together with the ﬁnding that human somatic cells could be con-
verted towards human induced pluripotent stem cells (hiPSCs) [2]
opened new venues for the production of protocols aiming to
generate patient cardiac-like cells (CLCs) with an impact in heart
regenerative therapies [3]. Recently, organ decellularization is
envisioned as an attractive strategy for the development of bio-
functional organs for drug screening and personalized medicine
[4e8]. In the last years, several works have proved the feasibility to
use cardiac extracellular matrix (ECM) from murine, pig or rat
origin for cardiac engineering using human ESCs (hESCs) [9e11].
Interestingly, CLCs derived from human iPSCs (hiPSCs-CLCs) have
recently proved to repopulate human hearts [4]. Herewe describe a
rapid protocol for the generation of human cardiac grafts by co-
culturing hESCs and hiPSCs (human pluripotent stem cells-hPSCs)
on cardiac ECM from human origin avoiding the use of extensive
culture in bioreactors. Moreover, our experimental setting allowed
for the investigation of the effect of human ventricular decellular-
ized ECM (vdEMC) on electrophysiological responses related to
cardiac function.
Protocols for derivation of cardiac like cells (CLCs) from hPSCs
(hPSCs-CLCs) have traditionally relied on the time consuming
production of embryoid bodies (EBs), achieving low yields of CLCs
generation, thus hampering the reproducibility and scale up of such
procedures [3,12,13]. Interestingly, in the last years several authors,
including us, have demonstrated that is possible to induce cardiac
differentiation from hPSCs grown as monolayers [14e17]. Although
challenging, those protocols still did not provide exact information
about the identity of the generated cells. In this regard, the gen-
eration of cardiac hPSCs reporter cell lines may lead to the deﬁni-
tion of the developmental cues driving cardiac differentiation, and
more importantly, to develop rapid methods for the enrichment of
different cardiac cell types during the onset of differentiation. So far
only two previous reports using Bacterial Artiﬁcial Chromosome
(BACs) showed the possibility to target cardiac-related loci in hPSCs
by homologous recombination [18,19]. In the same manner,
transposon-based approaches have led to the generation of hESCs
reporter cell lines for cardiac differentiation [20,21]. These studies
showed that reporter hPSCs lines could lead to the identiﬁcation of
novel markers for hPSCs-CLCs generation and expansion in vitro. In
the last years, genome editing technologies as CRISPR/Cas9 and
TALEN platforms, have emerged as powerful tools for targeting in
site-speciﬁc manner unique and multiple human loci, allowing to
study gene function, disease modeling and drug discovery, among
other applications. To our knowledge, neither CRISPR/Cas9 nor
TALEN platforms have been explored for the generation of cardiac
reporter hPSCs lines.
MYH6 is an important transcription factor essential for cardiac
muscle contraction, and recently, mouse MYH6-GFP ﬁbroblasts
have been used for the study of cardiac conversion [22]. Based on
those ﬁndings, and taking advantage of TALEN technology, we have
targeted human MYH6 locus with mCherry ﬂuorescent reporter
preserving the regulatory sequences near the native ATG start
codon for translation of MYH6 gene. In our hands, TALEN engi-
neering and subsequent cell culture pressure did not hamper
mCherry MYH6 reporter hESC line to exhibit classical pluripotent-
related features, and more importantly, enabled us to deﬁne a
robust protocol for the generation of CLCs from different hPSC lines.
Next, we made use of our recently reported method of perfusion
decellularization in human hearts for the generation of vdECMs
constructs. After only 10 days, hPSCs-CLCs grown on human
vdECMs exhibit a higher degree of physiological and molecular
cardiac differentiation compared to hPSCs-CLCs counterpartscultured in matrigel substrates. Overall, here we set up a rapid
protocol for the development of human heart grafts for drug
screening and disease modeling applications.
2. Methods
2.1. Donor heart harvest and heart decellularization
Between May 2010 and June 2013, we harvested 52 human
hearts that were determined by the Spanish National Transplant
Organization (ONT) as not suitable for transplantation. The ONT is
part of the Spanish Ministry of Health and Consumption and is in
charge of coordinating the donation, extraction, preservation, dis-
tribution, exchange, and transplantation of organs, tissues, and cells
throughout the Spanish Health Care System. Approval for all
studies was obtained from the relevant investigation and ethics
committees of the Hospital General Universitario Gregorio
Mara~non on and from the ONT. The relatives of each donor pro-
vided an informational brochure stating that the heart would be
used for this investigational purpose. After approval was obtained,
and other organs suitable for transplantation were explanted, we
used standard transplantation protocols to remove the heart.
Brieﬂy, a median sternotomy was performed to expose the medi-
astinum, the pericardiumwas opened, and the superior and inferior
vena cava were dissected. The hearts were maintained in saline at
4 C until decellularization was performed within few hours after
harvesting.
We used our previously described perfusion decellularization
protocol to remove the cells from the heart while retaining the ECM
[5]. Brieﬂy, hearts were perfused with 1% sodium dodecyl sulfate
(SDS) in deionized water via antegrade ﬂow through the ascending
aorta; perfusion was stopped at day 4e8. Hearts were then rinsed
extensively with approximately 20 L of phosphate-buffered saline
(PBS). Thirteen hearts were not decellularized and served as
cadaveric controls. Thick slices (400 mm) of decellularized heart
ventricles were obtained using a vibratome, and further seeded
with hPSCs-CLCs. Slices were kept at 4 C in PBS in the presence of
penicillin and streptomycin (Penicillin 10.000 U/ml:Streptomycin
10.000 mg/ml-Invitrogen#15140-122) until further use.
2.2. DNA quantiﬁcation
To assess total DNA content in the ECM scaffolds, samples were
digested as described previously [23]. After isolation, DNA content
was quantiﬁed using the Picogreen DNA assay following manu-
facturer's instructions (Invitrogen).
2.3. Cell lines
Control ﬁbroblasts (ATCC® SCRC-1041) were grown in DMEM
supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
0.1 mM 2-mercaptoethanol, nonessential amino acids and
penicillin-streptomycin (Penicillin 10.000 U/ml:Streptomycin
10.000 mg/ml-Invitrogen#15140-122). hESC ES4 line from Banco
Nacional de Lineas Celulares and hiPSCs (FiPS#1 line) were grown
in mTeSR1 (05850, Stem Cell Technologies) in matrigel substrate
(354277, Corning) following manufacturer recommendations.
2.4. Antibodies
The following antibodies were used: tumor rejection antigen 1
(TRA-1), TRA-1e81 (MAB4381, 1:100, Chemicon); OCT-3/4 (sc-
5279, 1:25, Santa Cruz Biotechnology); NANOG (AF1997, 1:25, R&D
Systems); Paired Box 6 (PAX6, PRB-278P, 1:100, Covance);
Microtubule-Associated Protein 2 (MAP2, sc-32791, 1:25, Santa
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Forkhead Box Protein A2 (FOXA-2, AF2400, 1:50, R&D Systems); a-
sarcomeric actinin (ASA, A7811,1:100, Sigma); RFP (ab34771,1:400,
Abcam); Myosin Heavy Chain (MYH6, GTX20015, 1:100, GeneTex);
GATA 4 binding 4 (GATA4, sc9053, 1:25, Santa Cruz Biotechnology);
NKX2.5 (sc8697, 1:25, Santa Cruz Biotechnology); Troponnin T
(TNN, MS-295-P1ABX, 1:500, Thermo Scientiﬁc); Collagen Type IV
(CIV22; ref: 760-2632; Dako); Actin Muscle Speciﬁc (HHF 35; ref:
760-260; Roche); Desmin (DE-R-11; ref 760-2513; Roche). Sec-
ondary antibodies used were all the Alexa Fluor Series from Jackson
Immunoresearch (all 1:200). For immunohistochemistry anti-
Mouse HRP-DAB Cell & Tissue Staining Kit (R&D, CTS002). Images
were taken using a Leica SP5 confocal microscope and Nikon-
TE200.
2.5. Genome editing of human embryonic stem cells with TALENs
TALENswere designed and assembled as described [24,25]. Each
TALEN consists of 34 amino acids, where the TALEN repeat variable
diresidues (RVDs) in the 12th and 13th amino acid positions of each
repeat specify the DNA base being targeted according to the code:
NG ¼ T, HD¼ C, NI ¼ A, and NN ¼ G or A. Tandem arrays of
customized TALE repeats were assembled using hierarchical liga-
tion and combining separate digest and ligation steps into single
Golden Gate reactions [26,27]. First, each nucleotide-speciﬁc
monomer sequence: NI, HD, NG, NN (from TALE Toolbox kit
Addgene cat no: 100000019) was ampliﬁed with ligation adaptors
that uniquely specify the monomer positionwithin the future TALE
tandem repeats, thus generating a monomer library. Once TALEN
targeting sites were identiﬁed using TAL effector Nucleotide Tar-
geter program [28], for each 20 bp TALEN target desired (50 and 30),
the appropriate monomers were ligated into hexamers and
ampliﬁed via PCR (speciﬁc primers were provided in TALE toolbox
kit Addgene cat no: 100000019- Table S1). Then, by a second
Golden Gate digestion-ligation with the appropriate TALE cloning
back- bone (pCMV_NLS (NI,HD, NG, NN)_FokI), the desired MYH6
sequence-speciﬁc TALEN were fully assembled. TALEN Backbone
was a gift from Feng Zhang (Addgene plasmid # 31179) [24]. All
TALENs used theþ63 truncation point [25]. The complete sequence
of all TALENs used in this work is provided in supplementary in-
formation (Fig. S1). After Sanger analysis for veriﬁcation, HEK 293
cells were transfected with TALENs as described previously [25,29].
Four hundred thousand cells were transfected, and subsequently
genomic DNA was extracted without selecting for transfected cells
using DNeasy Blood & Tissue kit (Qiagen). TALEN activity was
assayed via Surveyor nuclease assay (Transgenomic) using the
following primers for the ampliﬁcation of the expected targeting
area: Surveyor MYH6 Forward 5’- cactcagcgccaacccttagcatactccag-
30 and SurveyorMYH6 Reverse 5’-ccaggggtgattctcttggctggtgtgag-3'.
Primers were used at a ﬁnal concentration of 1 mM each in 50 mL
reactions using TAKARA LA Taq pol Hot Start (Takara). PCR reactions
were as follows: an initial denaturation step (94 C, 1 min); next, 35
cycles of a denaturation step of 20 s at 94 C, annealing and
extension step of 5min at 68 C, and a ﬁnal extension step of 10min
at 72 C. After absolute quantiﬁcation of PCR products, 800 ng were
used to perform the DNA heteroduplex formation on a 96 well
thermocycler with programmable temperature stepping function-
ality (Applied Biosystems) and following transgenomic Surveyor
mutation detection kit (Life Technologies) indications.
2.6. MYH6 donor vector (d-vector) design and construction
MYH6 donor vector (MYH6 d-vector) was generated by In-
Fusion® cloning method (Clonetech) following manufacturer's in-
dications. MYH6 genomic sequence was purchased in BACPACResources Center (RP11-929J10; BPRC) and used as template for
1 Kb homology arms ampliﬁcation by PCR. Then, HA_mCherry_Poly
cassette was ampliﬁed from pCAG_HA_mCherry_Poly based vector
from The Scripps Institute [30] by adding an extra Kozac sequence
to enhance mCherry future expression. A ﬁrst In-Fusion® reaction
was done with 25 ng of pZero_FRT_Neo [31] double digested with
BamHI and NdeI restriction enzymes (New England Biolabs) and
pZero_5'arm_HAmCherry_FRT_Neo was generated. Next MYH6 30
homology arm was cloned by a second In-Fusion® reaction on
pZero_5'arm_HAmCherry_FRT_Neo vector digestedwith EcoRV and
XhoI restriction enzymes (New England Biolabs) to generate a ﬁnal
donor vector: pZero_5'arm_HAmCherry_FRT_Neo_3'arm (Fig. S2).
PCRs were performed with primers listed on Table S2. PCR condi-
tions were: 3 min at 94 C; 30 cycles of denaturation at 94 C for
30 s, primer annealing at 60 C for 30 s, extension at 68 C for
1e2 min and ﬁnal extension step of 5 min at 65 C.
2.7. Targeting of hESCs using TALEN mediated homologous
recombination
ES4 was cultured in 10 mM Rho Kinase (ROCK)-inhibitor (Cal-
biochem; Y-27632) 1e3 h prior to electroporation. Cells were har-
vested using Accumax (Stem Cell Technologies cat no 07921) and
1 106 cells resuspended in 800 mL phosphate buffered saline (PBS)
and 15 mg of each pair of TALEN constructs (30 mg total) plus 30 mg of
donor vector were added into cell suspensions. Electroporation
conditions were ﬁxed at 500 mF; 200U; 250 V in Gene Pulser
Xcell™. 72 h after electroporation cells were selected by the
acquisition of Neomycin resistance adding 50 mg/ml of Neomycin
(G418, GIBCO). Targeted clones were selected by two different PCR
reactions with GXL polymerase (TAKARA). Primers for short and
long PCR products are listed in Table S3.
2.8. Southern blot analysis on targeted ES4 clones
Genomic DNA from ES4 clones positive for targeting by PCR
screening was isolated using All Prep DNA/RNA columns (Qiagen)
following manufacturer's guidelines. Brieﬂy, 5 mg of genomic DNA
was digested with 40 U of BclII restriction enzyme (New England
Biolabs) overnight and separated by electrophoresis on a 1%
agarose gel. Next, DNA was transferred to a neutral nylon mem-
brane (Hybond-N, Amersham) and hybridized with DIG-dUTP
labeled probes generated by PCR using the PCR DIG Probe Syn-
thesis Kit (Roche Diagnostics). Probes were detected by an AP-
conjugated DIG-Antibody (Roche Diagnostics) using CDP-Star
(Sigma-Aldrich) as a substrate for chemiluminescence. Primers
for probe synthesis are listed in Table S4. Genomic DNA from clone
#3 was veriﬁed by Sanger (Fig. S3).
2.9. Reprogramming of human ﬁbroblasts
Episomal plasmids published elsewhere [32] were used to
generate hiPSCs lines in a period of only 20e22 days. Fibroblasts
were cultured and maintained in ﬁbroblasts media: DMEM (Invi-
trogen, cat.no. 11965-092), 10% FBS (Invitrogen, cat. no. 10270-106),
1 mM Glutamax (Gibco®, Life Technologies cat no.35050-038) and
50 U/ml, 50 mg/ml of Penicillin/Streptomycin (Gibco®, Life Tech-
nologies cat no.15140-122) in a humidiﬁed 37 C 5% CO2 incubator.
When cells reached 80% of conﬂuence, 500.000 of cells trypsinized
with 0.25% Trypsin/EDTA (Invitrogen, cat. no. 25200-056) and
washed with PBS. Next, cells were resuspended in pre-warmed
Human MSC Nucleofector Solution at room temperature. Nucleo-
fector Solution was prepared following Human MSC Nucleofector®
Kit recommendations (VPE-1001, Amaxa). Then, plasmid mixture
containing 1 mg of each pCLXE episomal based plasmid were added
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27078), pCXLE-hOCT3/4-shp53-F (Addgene plasmid #27077),
pCXLE-hUL (Addgene plasmid #27080) were a gift from Shinya
Yamanaka]. Nucleofection reaction was performed in a provided
Amaxa certiﬁed cuvette using nucleofection program U-23 from
the Nucleofector™ 2b Device (Amaxa cat.no. AAB-1001). Cells were
immediately transferred into two wells of a six-well culture plate
with pre-warmed ﬁbroblast culture media and incubated for 4
additional days with daily media change. Finally, nucleofected cells
were subcultured onto matrigel (354277, Corning) coated plates in
the presence of mTeSR1 (05850, Stem Cell Technologies).
2.10. Induced pluripotent stem cells generation and subculture
On day 23 hiPSC colonies were picked manually and expanded
in matrigel (354277, Corning) coated plates in the presence of
mTeSR1 (05850, Stem Cell Technologies). From this stage on hiPSC
colonies were ampliﬁed by trypsinization in matrigel (354277,
Corning).
2.11. Immunocytochemistry and ﬂuorescence microscopy
ES4 and ES4 TALEN mCherry_MHY6/wt #3 (ES4 mCherry_-
MYH6), FiPS#1 line, hPSCs-CLCs, ventricular decellularized ECMs
(vdECMs) and recellularized vdECMs were ﬁxed in 2% para-
formaldehyde in PBS. After ﬁxation, samples were blocked and
permeabilized for 1 h at room temperature in the presence of 0.5%
Triton X100 and 6% donkey serum. Subsequently, samples were
incubated with the indicated primary antibodies overnight at 4 C.
Samples were thenwashed thrice with PBS and incubated for 2 h at
room temperature with the respective secondary antibodies.
Samples were washed thrice with PBS and counterstained with
DAPI (Invitrogen) before analysis. Samples were imaged using a SP5
(Leica) microscope.
2.12. RT-PCR analysis
Total RNA was isolated using All Prep RNA columns (Qiagen)
according to the manufacturer's recommendations. 2 mg of
TURBO™ DNase (Ambion, AM2238) treated total RNA was used for
cDNA synthesis using the SuperScript II Reverse Transcriptase kit
for RT-PCR (Invitrogen). Real-time PCR was performed using the
SYBR Green PCR Master Mix (Applied Biosystems) in an ABI Prism
7300 thermocycler (Applied Biosystems) and primers (Table S5).
2.13. In vitro differentiation of human pluripotent stem cell lines
ES4 mCherry_MYH6 line was differentiated in vitro towards the
three germ layers of the embryo. Monolayers of hPSCs were dis-
aggregated and subsequently induced to form Embryoid Bodies
(EBs) by centrifugation of cells within round-bottomed low
attachment 96-well plates at 950 g for 5 min as described else-
where [33]. After 3e4 days EBs were transferred to 0.1% gelatin-
coated glass chamber slides and cultured in differentiation me-
dium (DMEM supplemented with 20% fetal bovine serum, 2 mM L-
glutamine, 0.1 mM 2-mercaptoethanol, nonessential amino acids
and penicillin-streptomycin) for 2e3 weeks to allow spontaneous
endoderm formation. The medium was changed every other day.
For mesoderm differentiation, EBs were maintained on gelatin-
coated glass chamber slides in differentiation medium supple-
mented with 100 mM ascorbic acid (Sigma). For ectoderm differ-
entiation, EBs were cultured on matrigel coated glass chamber
slides in N2B27 medium (DMEM/F12 and neurobasal medium 1:1
supplemented with 1% N2 (Invitrogen), 0.5% B27 (Invitrogen),
2 mM L-glutamine and penicillin-streptomycin) supplementedwith 1 mM retinoic acid (Sigma) for 2e3 weeks. The medium was
changed every other day.
2.14. In vitro generation of cardiomyocyte-like cells (CLCs) from
human pluripotent stem cells (hPSCs)
Single cell suspension of hPSCs were seeded onto matrigel (BD
Biosciences) pre-coated cell culture dishes at a density of
125,000 cells per cm2 in mTeSR medium (StemCell Technologies).
Cells were then maintained in mTeSR for 48 h. Differentiation was
initiated by treatment with 12 mM CHIR99021 (Selleck) in RPMI
(Invitrogen) supplemented with B27 minus insulin (Life Technol-
ogies), 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, nonessential
amino acids and penicillin-streptomycin (RPMI/B27-insulin me-
dium) for 24 h (day 0 to day 1). On day 1, inhibitor was then
removed by intensive washing once with RPMI and medium was
changed to RPMI/B27-insulin. On day 3, cells were treated with
5 mMWnt inhibitor IWP4 (Stemgent) in RPMI/B27-insulin medium
and cultured without medium change for 48 h. On day 5, cells were
washed once with RPMI to eliminate the inhibitor and maintained
in RPMI (Invitrogen) supplemented with B27 (Life Technologies),
2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, nonessential amino
acids and penicillin-streptomycin (RPMI/B27 medium). From day 5,
cells were maintained in RPMI/B27 medium with medium change
every 2 days. On day 14, beating monolayers were obtained.
2.15. Flow cytometry
Cells were disaggregated from cell culture plates by incubation
with Accumax (Invitrogen) for 5 min at 37 C. Cells were vortexed
to disrupt the aggregates, and neutralized by adding DMEM me-
dium containing 10% fetal bovine serum (FBS). Next cells were
washed once in PBS without Ca/Mg2þ supplemented with 0.1 mM
EDTA (ﬂuorescence-activated cell sorter (FACS) buffer), and resus-
pended in 500 mL of FACS buffer for analysis. Approximately one
million cells were used for each ﬂow sample. Data were collected
and analyzed on an Aria FUSION (Becton Dickinson) ﬂow
cytometer.
2.16. Second harmonic generation (SHG) and two-photon excited
ﬂuorescence (TPEF)
Heart ECM was imaged by a nonlinear technique of SHG and
TPEF. This technique enables noninvasive visualization of collagen
and elastin in intact unstained tissues [34e36]. Collagen is a non-
centrosymmetric molecule that efﬁciently generates the second
harmonic of incident light, while elastin is a signiﬁcant source of
ECM autoﬂuorescence that can be imaged by TPEF. The SHG-TPEF
setup consisted of a Leica inverted confocal laser scanning micro-
scope SP-5 with META scanning module equipped with a mode-
locked near-infrared MAITAI Wide Band (710 nm-990 nm) laser
(Spectra Physics Millennia Pro 10sJ). The exciting laser beam was
tuned to 900 nm and the SHG collagen signal was obtained using a
447e453 nm bandpass ﬁlter. The TPEF signal was collected in a
second channel by tuning the exiting laser beam to 810 nm, using a
460e600 nm bandpass ﬁlter. DAPI stained nuclei in hPSCs-CLCs
grown on vdECMs were detected in the same channel as elastin.
Images were taken using a Leica HCX PL APO CS 40.0  1.25-NA oil-
immersion objective.
2.17. Strain analysis
Measurements of contractile strain were performed by
recording high resolution microscopical movies by using a
(EMCCD; Evolve-128: 128  128, 24  24 mm-square pixels, 16 bit;
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Microscope MVX10 (0.63  objective). Speciﬁcally, 500 frames per
second were acquired with a spatial resolution of 39 mm per pixel.
Total area covered by the image was 5  5 mm. Custom software
written in MATLAB was used tomeasure the deformation of culture
due to cardiac cells contraction. Maximal strain capacity was
measured as the ratio of elongation in the direction of maximal
contraction.
2.18. Optical mapping
Simultaneous voltage and calcium imaging was developed by
recording emission light of di-4-ANBDQPQ (provided by Dr Leslie
M. Loew from the Richard D. Berlin Center for Cell Analysis and
Modeling, University of Connecticut Health Center, USA) and rhod-
2(AM) (Ca2þ sensitive probe, TEFLabs, Inc, Austin, TX. USA)
respectively. The optical mapping system (Essel Research, Toronto,
Canada) consisted in a multiple light-emitting diodes as excitation
light sources and a high-speed an electron- multiplying charge-
coupled device (EMCCD) camera as recording system [37]. Specif-
ically, in order excite voltage dye di-4-ANBDQPQ, cell cultures were
illuminated with a ﬁltered red LED light source: LED CBT-90-B
(peak power output 53 W; peak wavelength 460 nm; Luminus
Devices, Billerica, MA, USA)with a plano-convex lens (LA1951; focal
length 0 25.4 mm; Thorlabs, New Jersey, USA) and a red excitation
ﬁlter (D470/20X (Chroma Technology, Bellows Falls, VT, USA). In
order to excite calcium dye rhod-2, cell cultures were illuminated
with a ﬁltered green LED light source: LED: CBT-90-G (peak power
output 58 W; peak wavelength 524 nm; Luminus Devices, Billerica,
USA), with a plano-convex lens (LA1951; focal length ¼ 25.4 mm;
Thorlabs, New Jersey, USA) and a green excitation ﬁlter (D540/25X;
Chroma Technology, Bellows Falls, USA). Two such light sources
were used to achieve homogeneous illumination. Fluorescence was
recordedwith EMCCD camera (Evolve-128: 128 128, 24 24 mm-
square pixels, 16 bit; Photometrics, Tucson, AZ, USA), with a custom
multiband-emission ﬁlter (ET585/50-800/200 M; Chroma Tech-
nology) placed in front of a high-speed camera lens (DO-2595;
Navitar Inc., Rochester, USA). Custom software written in MATLAB
was used to control the system and to perform optical mapping
image processing.
2.19. Optical mapping dye loading
For calcium transient (CaT) imaging, hPSCs-CLCs were stained
by immersion in 3 mL of a modiﬁed Krebs solution at 36.5 C
(containing, in mM: NaCl, 120; NaHCO3 25; CaCl2 1.8; KCl 5.4;
MgCl2 1; glucose 5.5; H2O4PNa$H2O 1.2) with rhod-2 AM dissolved
in DMSO (1 mM stock solution; 3.3 ml per ml in culture medium)
and Probenecid (TEFLabs, Inc, Austin, TX, USA) at 420 mM for 30min
under incubation conditions. After calcium dye incubation, culture
mediumwas changed to fresh modiﬁed Krebs with di-4-ANBDQPQ
voltage dye [38] dissolved in pure ethanol (27.3 mM stock solution,
2 ml per ml in culture medium) and Pluronic F-127 (Life Technol-
ogies) was added to a ﬁnal concentration of 0.2e0.5%]. After voltage
dye incubation during 5 min, culture mediumwas changed to fresh
Krebs solution at 36.5 C supplemented with 10 mMblebbistatin. All
chemicals were obtained from Sigma-Aldrich (Dorset, UK) or Fisher
Scientiﬁc Inc. (New Jersey, USA).
2.20. Spinning disk confocal microscopy
Images of beating hPSCs-CLCs monolayers and co-cultures on
vdECMs were acquired using a CFI Plan Achromat UW 2 objective
in a spinning disk confocal microscope (Andor). hPSCs-CLCs cul-
tures were maintained at 37 C in RPMI/B27 medium and imagedevery 50 and 100 m for 20e30 s. Images were exported into ImageJ
for processing.
2.21. Statistical analysis
Data are mean ± SD. mRNA expression by qPCR during the time
course of cardiac differentiation was analyzed with one-way
ANOVA and Bonferroni post-test. Different letters indicate signiﬁ-
cant difference between groups (p < 0.05). When analyzing sta-
tistical differences between two different experimental groups
(matrigel and vdECMs culture systems) two-tailed student's t-test
was used. Results were considered statistically signiﬁcant if the p-
value was less than *0.05, **0.01 and ***0.001. Statistical analysis
were performed using Graph Pad 5.0 and SPSS (v.11).
3. Results
3.1. TALEN-mediated targeting of the MYH6 locus in human
embryonic stem cells (hESCs) does not affect pluripotency-
associated features
We made use of TALEN technology to target the MYH6 human
locus in hESC, namely ES4 line (Fig. S4). Following design and as-
sembly of the in silico designed TALEN pairs (Table S1) TALEN
endonuclease-associated activity was tested in HEK293 cells prior
to genome engineering of ES4 line by means of Surveyor nuclease
assay (Fig. S5). We then evaluated the efﬁciency of the best TALEN
pair for producing a knock in reporter allele by targeting the MYH6
human locus using drug selection. The DSB induced in ES4 line was
subsequently repaired through homologous recombination (HR)
with MYH6 donor vector (Fig. 1A). Thus after clone expansion and
antibiotic selection we identiﬁed 24 putative mCherry_MYH6 tar-
geted ES4 clones resistant for Neomycin that were subsequently
analyzed by PCR screening, identifying a total of 18 out of 24
positively targeted ES4 clones when TALEN pair 1 was used
(Fig. S6). Southern blot analysis was performed in 4 out of 18 pu-
tative MYH6 targeted clones, revealing that 3 of them contained a
MYH6 targeted allele (Fig. S7).
We proceed to characterize one of those clones, namely ES4
TALEN mCherry_MHY6/wt #3 (ES4 mCherry_MYH6), for the
expression of nuclear transcription factors as OCT4, NANOG and
TRA-1-81 surface marker by immunoﬂuorescence, conﬁrming their
pluripotent nature (Fig. 1B). We next explored if gene targeting
hampered ES4 mCherry_MYH6 differentiation towards the three
germ layers of the embryo and we found that ES4 mCherry_MYH6
line exhibited the capacity to generate cells from ectodermal,
mesodermal and endodermal lineages (Fig. 1C). Remarkably,
mCherry expressionwas limited to the cardiac mesodermal lineage
and not found in the ectoderm and endoderm germ layers, indi-
cating a proper response of our reporter cell line under differenti-
ation (Fig. 1C). In addition, ES4 mCherry_MYH6 line exhibited the
classical ES-associated morphology (Fig. 1D, top panel), and
continued to express pluripotent-related markers, including
Dppa4, Nanog, Oct4, Rex1, Sox2, Cripto, Dnmt3b, Sall2 and Utf1
(Fig. 1D, bottom panel).
3.2. Chemically deﬁned media sustains cardiac differentiation from
hPSCs
To demonstrate that ES4 mCherry_MYH6 line recapitulated
MYH6 activity, we established a protocol for the generation of
cardiac-like cells (CLCs) from hPSCs (hPSCs-CLCs) grown as
monolayers based on a stage speciﬁc activation and suppression of
the canonical Wnt signaling. Concisely, ES4 mCherry_MYH6 cells
were exposed to GSK3B inhibitor (CHIR99021) from day 0 to day 1,
Fig. 1. TALEN engineering in hESCs. A. MYH6 donor vector includes a mCherry cassette HA-tagged (HA), a PGK promoter and a neomycin-kanamycin resistant cassette (Neo/Kan);
both ﬂanked by FRT sites. Dashed lines indicate the sites of HR in the MYH6 locus. HR results in knock in of the complete cassette into the ATG start site of MYH6 locus, generating a
mCherry-taggedMYH6 allele. B Immunodetection for OCT4, NANOG and TRA-1e81 in ES4 mCherry_MYH6 line, (scale bars, 50 mm). Note mCherry signal was not detected. C In vitro
differentiation of ES4 MYH6_mCherry line into ectoderm [Microtubule-Associated Protein 2 (MAP2) and Paired Box 6 (PAX 6)], endoderm [a-fetoprotein (AFP), Forkhead box protein
A2 (FOXA2)], mesoderm [K2 Homeobox 5 (NKX2.5) and a-sarcomeric actinin (ASA)], (scale bars, 25 mm). D Top panel, representative contrast phase image of an undifferentiated ES4
mCherry_MYH6 clone that grows as a compact and tight adherent colony. Bottom panel, qPCR analysis for the evaluation of mRNA expression of pluripotency associated markers
after TALEN engineering in ES4 line. Data were represented as mean ± standard deviation.
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of differentiation. From day 5, monolayers were kept in RPMI/B27
medium (Fig. 2A). We further explored the expression of mCherry
ﬂuorescent reporter during the time course of differentiation and
observed that already at day 7 mCherry ﬂuorescent protein was
detected by optical microscopy (Fig. 2B left panel). In the same
manner mRNA expression analysis by qPCR showed that mCherry
mRNA expression mirrored endogenous MYH6 activity, indicating
the potential use of our cellular system to properly dissect cardiac
differentiation from hPSCs (Fig. 2B right panel). Moreover, ﬂow
cytometric analysis showed that mCherry protein expression was
present as soon as day 5 during differentiation, and that 14 days
after differentiation 90% of the cells expressed mCherry ﬂuorescent
protein (Fig. 2C).
We further assessed the proﬁle of mRNA expression during the
onset of cardiac differentiation in ES4 mCherry_MYH6 line, and
found out that our protocol induced the expression of mRNAs
related with early mesoderm and cardiac progenitors up to day 5
during differentiation (PDGFRa, ISL-1, c-KIT). The expression of
mRNAs related to cardiac program from day 5 to later stages during
differentiation (GATA4, NKX2.5, MYH6, MYL2, NPPA, TNNT2, MYL7)
was also analyzed. As expected, the levels of expression for
pluripotent-related mRNAs as OCT4, NANOG and SOX2 markedly
decreased from day 5 during differentiation (Fig. 3A and Fig. S8).
Full beating monolayers were obtained at day 14 of differentiation(Video S1 and S2). Beating monolayers of ES4 mCherry_MYH6
derived CLCs (mCherry-CLCs) were also characterized by immu-
noﬂuorescence for the expression of protein markers at day 14 of
differentiation, showing that mCherry-CLCs expressed major pro-
teins associated with cardiac structural function: Alpha Sarcomeric
Actinin (ASA), Troponin T (TNN), Myosin Heavy Chain (MYH6); and
nuclear transcription factors related to cardiac fate [K2 Homeobox 5
(NKX2.5)], together with Connexin 43 (CX43), a protein related to
electrical coupling (Fig. 3B, C). In order to investigate the robustness
of our protocol we further test our optimized culture conditions in
both hESCs (ES4) and transgene-free and feeder-free hiPSCs
derived from dermal ﬁbroblasts (FiPS#1). Full beating monolayers
were obtained from both ES4 and FiPS#1 lines after 14 days of
differentiation (Video S3 and Video S4). In addition, both ES4
(Fig. S9) and FiPS#1 (Fig. S10) expressed cardiac related markers at
the different selected time points as shown by qPCR. Similarly, both
ES4 and FiPS#1 expressed major proteins associated with cardiac
structural function after 14 days of differentiation, conﬁrming that
our culture conditions supported the generation of CLCs from
different hPSC lines (Fig. S11 and Fig. S12, respectively). Altogether,
our protocol sustained the derivation of hPSCs-CLCs monolayers in
the presence of chemically deﬁnedmedia, providing a reproducible
and efﬁcient method for the generation of hPSCs-CLCs on matrigel
coated plates.
Supplementary video related to this article can be found at
Fig. 2. mCherry targeting in MYH6 locus in ES4 line mirrors MYH6 activity during cardiac differentiation. A Time line of human ES4 mCherry_MYH6 cardiac differentiation. B
Left panel, optical microscopy for mCherry detection in ES4 mCherry_MHY6 after 7 days of cardiac differentiation. Right panel, evaluation of mRNA expression of mCherry reporter
and MHY6 gene by qPCR in ES4 mCherry_MYH6 line during the time course of cardiac differentiation at the indicated days. Data were represented as mean ± standard deviation.
Different letters indicate signiﬁcant differences between groups (p < 0.05) C FACS analysis for mCherry ﬂuorescent protein during the time course of cardiac differentiation in ES4
mCherry_MYH6 at the indicated days.
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3.3. In vitro recellularization of human ventricular decellularized
matrices (vdECMs) with hPSCs-CLCs
Next, we applied our previously published protocol of perfusion
decellularization to generate human vdECMs scaffolds that pre-
served three dimensional architecture and vascular integrity [5].
Following this protocol, we prepared 400 mm thick vdECMs slices to
seed hPSCs-CLCs at day 14 of differentiation in order to explore the
effect of human cardiac vdECM on hPSCs-CLCs functional activity
and differentiation. Prior to recellularization, immunohistochem-
istry against proteins from the cellular compartment including
muscle speciﬁc actin and desmin, as well as basement membrane
proteins of the ECM, such as collagen IV, revealed the absence of
cellular content and retention of collagen IV in decellularized heart
tissue scaffolds (Fig. S13A). In addition, residual DNA content in
vdECMs was less than 3% (Fig. S13B), conﬁrming a major removal ofnuclear material. Furthermore, immunoﬂuorescence analysis for
laminin, collagen IV and elastin conﬁrmed the preservation of these
ECM components in our vdECMs, similarly to those in the native
heart (Fig. 4A). Indeed, the presence of a dense ﬁbrillary collagen
microstructure was observed on vdECMs by SHG-TPEF microscopy
(Fig. 4B). DAPI staining was not visible in vdECMs, indicating again
the loss of cellular material (Fig. 4A, B). Overall, our results sug-
gested that our decellularization protocol sufﬁced for the produc-
tion of cardiac scaffolds that accomplished the established criteria
of decellularization [39].
Next, we set up a protocol for the generation of small heart
constructs for cardiac engineering by culturing mCherry-CLCs on
vdECMs under our chemically deﬁned conditions for 10 additional
days. Thick slices of vdECM supported the engraftment of mCherry-
CLCs, which could adhere and cover the scaffold. In this manner,
spontaneously beating slices were produced and maintained in
culture for 10 days (Fig. 5A). mCherry-CLCs continued to express
major proteins associated with cardiac structural function [Alpha
Fig. 3. Generation of CLCs from ES4 mCherry_MYH6 line. A mRNA analysis by qPCR analysis for different genes related to cardiac program and pluripotency network at the
indicated days (n ¼ 3). Data were represented as mean ± standard deviation. Different letters indicate signiﬁcant differences between groups (p < 0.05). B Immunoﬂuorescence
analysis for MYH6, NKX2.5, and mCherry in mCherry-CLCs at 14 days of differentiation (scale bars, 25 mm). C Immunoﬂuorescence analysis for ASA, Troponin T (TNN), Connexin 43
(CX43) and mCherry in mCherry-CLCs at 14 days of differentiation (scale bars, 25 mm).
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(MYH6)], nuclear transcription factors related to cardiac fate [K2
Homeobox 5 (NKX2.5)] and CX43 (Fig. 5B), indicating the mainte-
nance of the cardiac phenotype after 10 days of culture with
vdECMs. Interestingly, the generated cardiac grafts showed uni-
form contraction (Video S5 and Video S6), indicating the presence
of cell-cell interconnections as well as cellular interactions with the
vdECM. We subsequently transferred the same culture conditions
to fabricate cardiac grafts from both ES4 derived CLCs (ES4-CLCs)
and FiPS#1 derived CLCs (FiPS#1-CLCs). Cardiac grafts generated
from both ES4-CLCs and FiPS#1-CLCs showed similar characteris-
tics in terms of cardiac proteins expression (Fig. 6A and Fig. 6B,
respectively) and uniform contraction (Video S7 and Video S8,
respectively), conﬁrming the robustness of our method. Moreover,
to characterize the mechanical function of the spontaneously
beating human cardiac grafts, we determined the contractile strain
of hPSCs-CLCs seeded on vdECM by measuring the relative cardiac
graft deformation in the direction of maximal tissue contraction.
Human cardiac grafts exhibited a 3.78-fold increase in strain
compared to hPSCs-CLCs cultured on matrigel (15.53 ± 3.33% and
4.21± 0.93%, respectively) (Fig. S14; Video S9 and Video S10). Theseresults are in agreement with previous ﬁndings when analyzing
myocardial strain in the human heart [40].
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.biomaterials.2016.04.003.
3.4. Human vdECMs promote a higher degree of differentiation in
hPSCs-CLCs when compared to matrigel, as assessed by
electrophysiological and molecular analysis
Next, we sought to evaluate if hPSCs-CLCs grown either on
vdECMs or matrigel presented electrically and mechanically con-
nected functional activity. Simultaneous recording of voltage and
calcium demonstrated the coordinated activity of cardiac structures
for all cases, indicating the functional gap junctions' interconnec-
tion between hPSCs-CLCs (Fig. 7A, B). Maturation degree was
evaluated by comparing the main electrophysiological properties
from optical mapping recordings at 1 Hz pacing rate [(i.e. wavefront
propagation conduction velocity (CV), mean action potential
duration at 90% repolarization (APD90), mean calcium transient
duration at 90% return to baseline (CaT90), and Ca2þ (Ca) Upstroke
Time] (Fig. 7CeF). We observed a dramatic increase in the CV when
Fig. 4. Characterization of vdECMs composition. A Immunoﬂuorescence analysis for LAMININ (LAM), COLLAGEN IV (COL IV), ELASTIN (ELASTIN) and DAPI staining in native
human heart (Native) and vdECMs (scale bars, 50 mm). B Native human heart and vdECMs were analyzed by Second harmonic generation (SHG) for the detection of Collagen (SHG-
Col) and by immunoﬂuorescence analysis for ASA and DAPI staining (scale bars, 50 mm).
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(7.45 ± 0.94 cm/s versus 2.54 ± 0.75 cm/s) (Fig. 7C). Similar results
were observed for FiPS#1-CLCs (8.30 ± 0.49 cm/s versus
2.03 ± 0.18 cm/s, respectively) (Fig. 7C). Increases in CV when
hPSCs-CLCs were cultured on vdECMs were related to a higher
degree of excitability of sodium current, as 10 mM ﬂecaidine infu-
sion resulted in a more signiﬁcant reduction of the conduction
velocity of hPSCs-CLCs (i.e. 63 ± 9% versus 44 ± 11% for hESC-CLCs
and 71 ± 13% versus 41 ± 5% for FiPS#1-CLCs) (Fig. 7H).
To assess if increases in the CV were also associated with higher
contraction capability due to differences in culture substrates, we
evaluated the kinetics of calcium as an indicative parameter of
hPSCs-CLCs maturation. hPSCs-CLCs cultured on vdECMs showed a
reduction in the duration of CaT90 and calcium upstroke time
compared to matrigel (Fig. 7E, F). Such variations were notassociated with signiﬁcant differences in the duration of APD90
(Fig. 7D). Speciﬁcally, faster calcium transient increases in hESC-
CLCs cultured on vdECMs were associated with a higher degree of
maturation of late inward calcium current (ICaL), since 4 mM
verapamil infusion resulted in a more signiﬁcant reduction of the
upstroke velocity of the calcium transient (Fig. 7G).
Moreover, we investigated if such ﬁndings could correlate with
differences at the level of mRNA expression (Fig. 7I). Increases in
the levels of expression of SCN5A mRNA when hPSCs-CLCs were
cultured on vdECMs compared to matrigel condition were in
agreement with increases in conduction velocities (Fig. 7C, H).
Similar results were found for inward rectiﬁer potassium current
(KCNJ2). Interestingly, increases in KCNJ2 are associated with lower
resting potential in cardiomyocytes, leading to higher conduction
velocities [41], as observed in Fig. 7C. So far, acquisition of KCNJ2
Fig. 5. Cardiac differentiation of ES4 mCherry_MHY6 derived CLCs on vdECMs. A Left panels, ES4 mCherry_MHY6 derived CLCs were cultured on top of vdECMs during 10 days
and further analyzed for mCherry ﬂuorescence together with the detection of collagen from the underlying vdECM by Second Harmonic Generation (SHG-Col) (scale bars, 250 mm).
Right panel, higher magniﬁcation image showing the ﬁbrillary microstructure of collagen from the underlying vdECM and elastin/nuclei by SHG-TPEF (scale bar, 50 mm). B
Immunoﬂuorescence analysis for: Top panels, MYH6, Nkx2.5 and detection of collagen by SHG (SHG-Col), (scale bars 25 mm). Middle panels, ASA, NKX2.5 and SHG-Col (scale bars
50 mm). Bottom panels, CX43, TNN and SHG-Col (scale bars 25 mm).
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production from hPSCs [41], indicating that under our deﬁned
conditions, vdECMs may play a role in the expression of this cur-
rent. Similarly, increases in the levels of expression of KCNA4mRNA
in hPSCs-CLCs suggested that vdECM, rather than matrigel, may
represent a more physiological microenvironment for the proper
differentiation of hPSCs-CLCs.
In order to ascertain the effect of the different substrates on
intracellular calcium homeostasis, mRNA expression levels of the
CACNA1C subunit from the L-type calcium channel current, and
sarco/endoplasmic reticulum Ca2þ ATPase (SERCA) pump were
investigated. Interestingly, hPSCs-CLCS co-cultured on vdEMCs
compared to matrigel, exhibited higher levels of expression of
CACNA1C and SERCA mRNAs [42], which correlated with increases
in calcium upstroke (Fig. 7F, G). mRNA levels of the KCNH2 unit of
the rapidly (IKr) activating delayed rectiﬁer potassium channel and
KCNQ1/2 [(two members of the potassium voltage-gated channel
subfamily Q of the slowly (IKs) activating delayed rectiﬁer potas-
sium channels)] were differentially regulated when hPSCs-CLCs
were cultured on matrigel or vdECMs conditions. These ﬁndings
may explain the similar duration of action potentials observed
(Fig. 7D). Altogether, our results suggest a pivotal role of vdECMs inproviding a suitablemicroenvironment for the in vitro generation of
hPSC-derived cardiac grafts.
4. Discussion
In humans, the existence of scar tissue following myocardial
infarction indicates that the ability to generate new cardiomyocytes
after pathological conditions is completely absent. Given that heart
disease is the most signiﬁcant cause of morbidity and mortality
worldwide, the possibility to replace ﬁbroblastic-like scar has been
one the major goals in the cardiac ﬁeld in the last years. So far,
different cell therapy approaches have been proposed: from the use
of allogenic cell sources alone or in combination with biomimetic
materials to the possibility to reprogram in situ cardiac ﬁbroblasts.
In an attempt to provide novel platforms for heart regeneration,
heart engineering has been envisioned as a promising approach for
the generation of donor grafts. Recently, the generation of acellular
matrices from different organs by decellularization has emerged as
an encouraging technology to produce tissue scaffolds that retain
the main properties of the organ ECM [7,8]. Within the last years,
different groups, including us, have faced major problems when
developing efﬁcient protocols for heart decellularization. In this
Fig. 6. Cardiac differentiation of hESC- and hiPSC- CLCs on vdECMs. A ES4-CLCs and B FiPS#1-CLCs were seeded on top of vdECMs during 10 days and further analyzed by
immunoﬂuorescence analysis for ASA and NKX2.5 (top panels in A and B), and CX43 and TNN (bottom panels in A and B) together with the detection of collagen by SHG (SHG-Col).
Scale bars in A, 50 mm. Scale bars in B, 100 mm (top panels) and 25 mm (bottom panels).
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perfusion decellularization in human hearts, leading to a structur-
ally intact decellularized extracellular matrix (dECM) preserving
ultra- and macro-structures together with mechanical properties
[5].
Besides the deﬁnition of suitable strategies for organ engineer-
ing, the choice of cell type for cardiac recellularization limits further
applications in clinics. Lately hPSCs, such as hESCs and hiPSCs, have
been heralded as major cell sources for regenerative applications,
including heart engineering. hPSCs exhibit the capability to differ-
entiate under the appropriated stimuli to cells from the three germ
layers of the embryo, both in vitro and in vivo. These capabilities
offer great advantages when trying to develop autologous cells fortransplantation. However, protocols for cardiac differentiation of
hPSCs are frequently based on the formation of EBs, hampering the
reproducibility and scale up of such procedures in clinics [3,12,13].
Lately, we have demonstrated that is possible to induce cardiac
differentiation from hPSCs grown as monolayers, making use of
chemically deﬁned media [16]. Although valuable, those protocols
still cannot provide deﬁnitive information on the identity of the
generated cells [14,16]. In this regard, the generation of cardiac
hPSCs reporter cell lines can help to the identiﬁcation and puriﬁ-
cation of different cardiac cell types during the onset of differen-
tiation (i.e: cardiac mesoderm precursors, cardiac progenitor cells,
mature cardiomyocytes, among others), and importantly, to
develop efﬁcient and robust protocols to generate the required
Fig. 7. Simultaneous optical mapping of transmembrane voltage and intracellular transient calcium of cardiac structures from hPSCs grown on vdECMs and matrigel. A, B
Simultaneous optical mapping of transmembrane voltage and intracellular transient calcium of hPSCs-CLCs on matrigel (A) and vdECMs (B). Grayscale images of normalized
ﬂuorescence intensity map. Middle panel illustrate the propagation of transmembrane voltage. Right panels represent transmembrane voltage (blue) and calcium transient (red)
traces of representative recorded pixels. CeF. Electrophysiological properties of hECS-CLCs and FiPS#1-CLCs grown on matrigel and vdECMs: C wavefront propagation conduction
velocity, D action potential duration (APD90), E calcium transient duration (CaT90) and F Calcium (Ca) upstroke time measured on hECS-CLCs and FiPS#1-CLCs grown on matrigel
and vdECMs. G Effect of verapamil on reduction of Ca upstroke time. H Effect of ﬂecainide on reduction of conduction velocity. I mRNA analysis by qPCR for the indicated markers
(n ¼ 3) (*p < 0.05; **p < 0.01, ***p < 0.001).
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Recent genome editing technologies including CRISPR/Cas9 and
TALEN platforms have demonstrated to target unique and multiple
human loci in site-speciﬁc manner. Interestingly, recent works have
investigated the impact of genome editing platforms in the inci-
dence of off-target mutations. In this regard it has been shown that
off-target mutations attributable to the nucleases were rarely
exhibited in CRISPR-Cas9 and TALEN targeted hPSCs clones [43].
We have also recently interrogated by whole-genome sequencing
the mutational load in individual gene-corrected hiPSC clones at
single-base resolution, showing that gene correction by helper-
dependent adenoviral vector (HDAdV) or TALEN exhibited few
off-target effects and a low level of sequence variation [44].
Importantly, others have described the generation of a high-ﬁdelity
Cas9 variant (named SpCas9-HF1) designed to reduce non-speciﬁc
DNA interactions, showing no detectable genome-wide off-target
effects [45].
Here we decided to take advantage of TALEN platform to target
MYH6 locus withmCherry ﬂuorescent reporter in order to generate
a reporter cell line mirroring MYH6 endogenous activity during the
onset of cardiac differentiation. In the present work, we have
derived three different mCherry MYH6 reporter hESC lines that
serve as an unprecedented scenario for the deﬁnition of a chemi-
cally deﬁned protocol for cardiac differentiation of hPSCs. In our
hands, gene targeting and subsequent cell culture pressure did not
hamper ES4 mCherry_MYH6 line to exhibit typical pluripotent-
related features, as described by others when targeting other hu-
man locus by means of this approach [24,29,46e48]. Following our
cardiac differentiation protocol, CLCs expressing mCherry ﬂuores-
cent protein were generated in only 7 days, mirroring MYH6
endogenous expression. Moreover, we could successfully apply the
same cardiac differentiation strategy to hPSCs lines, demonstrating
the suitability of our protocol for the generation of CLCs from
monolayer cultures of different hPSCs lines. In our hands, TALEN
engineering allowed not only to generate for the ﬁrst time a hESCs
cardiac reporter cell line by means of this genome editing platform,
but also, to deﬁne a robust protocol of cardiac differentiation from
hPSCs.
Important cell functions such as proliferation and differentiation
can be modulated by the biochemical and biophysical properties of
their microenvironment [49e51]. Mechanical cues from the ECM
including rigidity, microstructure and 3D architecture have shown
to exert changes in intracellular cell signaling cascades and sub-
sequently drive cell fate [52e54]. Elegant studies have previously
shown the beneﬁts when using murine cardiac ECM in promoting
cardiac differentiation from hPSCs [9,11]. Also, others have recently
demonstrated that engineered heart slices from pig and rat repre-
sented a suitable platform for the culture of neonatal rat ventricular
cardiomyocytes, behaving as an integrated and functional tissue-
like constructs [10]. Understanding cellular interactions of CLCs
with the ECM of human origin can have important implications in
the development of functional tissue engineered grafts from hPSCs.
Here, we show that hPSCs-CLCs co-cultured on human vdECMs for
10 days displayed better electrophysiological responses compared
to matrigel, which is mostly used to produce high yields of car-
diomyocytes from hPSCs. Importantly, our ﬁndings were together
in agreement with increases in the expression of different cardiac
channels such as SNCA5, KCNJ2, KCNA4, CACNA1C, SERCA2, KCNQ1,
and KCNQ2, pinpointing a pivotal role of human cardiac ECM as an
inducer of cardiac-related electrophysiological features.
5. Conclusions
Decellularization of a whole heart can lead to hundreds of
acellular slices ready to use as scaffolds for the approach describedhere. The present protocol allows for the generation of cardiac
grafts showing enhanced electrophysiological properties in a rela-
tively short time period (24 days), avoiding time consuming co-
culture techniques (i.e: bioreactor, perfusion system, among
others), and anticipating that such procedure can be immediately
applied in laboratories with special focus in heart bioengineering
and cardiac disease modeling.
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